Transdermal drug delivery system (TDDS) is emerging system as compared to oral and parentral. In TDDS, patch system was developed to control the release of drug and achieved advantages over the oral and parenteral. However, TDDS has limited market success due to the barrier properties of the Stratum Corneum and stability of formulation. Then after, the number of vesicular drug delivery systems such as liposomes, ethosomes, niosomes were developed as Novel transdermal drug delivery system (NTTDS). It delivers the drug at a rate directed by the needs of the body, over the period of treatment. Secondly, it channel the active entity to the site of action. Ethosome is better achievement in vesicular drug delivery system, helpful to achieve goal needed by NTDDS. Ethosomes are soft, malleable and noninvasive delivery carriers that enable drugs to reach the deep skin layers and/or the systemic circulation. Also, the ethosomal systems are conceptually sophisticated, characterized by simplicity in their preparation, safety and efficacy—a combination that can highly expand their application. It provides a number of important benefits including improving the drug's efficacy, enhancing patient compliance and reducing the total cost of treatment. Because of their unique structure, ethosomes are able to encapsulate and deliver the highly lipophilic molecules such as minoxidil as well as cationic drugs such as trihexyphenidil through the skin. Enhanced delivery of bioactive molecules through the skin by means of an ethosomal carrier opens numerous challenges and opportunities for the research and future development of novel improved therapies.
Loading....